STRATEC Biomedical AG / Key word(s): Change of Personnel
STRATEC - Chief Sales Officer to leave company
Birkenfeld, March 19, 2014
STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) today announces that Bernd M. Steidle (Member, Board of Management, Marketing and Sales) has left the Board of Management as of March 19, 2014 and will have no further involvement in the company's operations.
The Supervisory Board and Board of Management of STRATEC would like to thank Mr. Steidle for his longstanding commitment and significant achievements on behalf of STRATEC and wishes him all the best in his future endeavours.
Company structures in the fields of marketing and sales will now be realigned under the management of company CEO Marcus Wolfinger. In future, the responsibilities for marketing and sales will be managed at senior vice president level. There are no plans to appoint a new member of the Board of Management with responsibility for sales and marketing in the near future.
Further information can be obtained from:
End of Corporate News
19.03.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
|Company:||STRATEC Biomedical AG|
|Phone:||+49 (0)7082 7916 0|
|Fax:||+49 (0)7082 7916 999|
|Listed:||Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart|
|End of News||DGAP News-Service|